data stringlengths 198 8.84k | criteria stringlengths 39 16.5k | __index_level_0__ int64 0 22.4k |
|---|---|---|
Study Objectives
RATIONALE: Cyproheptadine and megestrol may improve appetite and help prevent weight loss in children with cancer.
PURPOSE: This phase II trial is studying how well cyproheptadine and megestrol work in improving appetite and preventing weight loss in children with cachexia caused by cancer or cancer t... | INCLUSION CRITERIA:
* Any cachectic patient with weight loss presumed secondary to cancer or cancer related therapy is eligible. Cachexia is defined as having one or more of the following:
* documented history of weight loss > 5%
* drop in growth rate two or more percentile ranks on standard growth charts,
* weight fo... | 7,278 |
Study Objectives
Understudied drugs will be administered to children per standard of care as prescribed by their treating caregiver and only biological sample collection during the time of drug administration will be involved. A total of approximately 7000 children aged \<21 years who are receiving these drugs for stan... | Inclusion Criteria:
* 1) Children (< 21 years of age) who are receiving understudied drugs of interest per standard of care as prescribed by their treating caregiver
Exclusion Criteria:
* 1) Failure to obtain consent/assent (as indicated)
* 2) Known pregnancy as determined via interview or testing if available. | 14,267 |
Study Objectives
The purpose of this study is to determine the feasibility and safety of administering CMV RNA-pulsed dendritic cells (DCs), also known as CMV-DCs, to children and young adults up to 35 years old with nWHO Grade IV glioma, recurrent malignant glioma, or recurrent medulloblastoma. Evidence for efficacy w... | Inclusion Criteria:
* Age requirements:
1. <= 35 years for patients with grade IV glioma or recurrent World Health Organization (WHO) grade IV glioma
2. 3-35 years old for patients with recurrent medulloblastoma
* Newly diagnosed or recurrent WHO grade IV glioma, recurrent WHO grade III glioma, or recurrent med... | 169 |
Study Objectives
Chronic myeloid leukemia (CML) is a hematopoietic neoplasm characterized by the reciprocal translocation t(9;22). The resulting oncoprotein, bcr-abl is an essential trigger for growth and survival of leukemic cells. In the past decade, the bcr-abl tyrosine kinase inhibitor (TKI) imatinib (IM or Glivec©... | Inclusion Criteria:
* Male and female patients
* Patient participating to the STIM trials (including STIM, STIM2 et EURO-SKI) and with confirmed molecular relapse on two consecutive RQ PCR, after imatinib discontinuation
* Still in chronic phase
* Not yet treated for this relapse
* At least 18 years old (no upper age ... | 7,359 |
Study Objectives
This is a multi center, open-label study to evaluate the drug-drug interaction of LDE225 on the PK of bupropion and warfarin patients with advanced solid tumors. Subjects will receive 800mg daily of LDE225 and two separate doses of either bupropion or warfarin.
Conditions: Advanced Solid Tumor
Interv... | Inclusion Criteria:
* Adults
* Patients with cytopathologically or histopathologically confirmed diagnosis of an advanced solid tumor which has progressed despite standard therapy, or for which no standard therapy exists or patients with locally advanced or metastatic basal cell carcinoma who are not amendable or elig... | 11,307 |
Study Objectives
This phase II trial is studying the side effects and how well decitabine works when given as maintenance therapy after standard therapy in treating patients with previously untreated acute myeloid leukemia. Drugs used in chemotherapy, such as cytarabine, daunorubicin, etoposide, busulfan, and decitabin... | Inclusion Criteria:
* Unequivocal histologic diagnosis of AML (> 20% blasts in the bone marrow based on the World Health Organization [WHO] and/or French American British [FAB] classifications), excluding M3 (acute promyelocytic leukemia); patients with antecedent myelodysplasia are eligible for treatment on this tria... | 12,105 |
Study Objectives
The purpose of this study is to test an investigational drug, vinflunine (BMS-710485), in combination with gemcitabine in patients with Transitional Cell Carcinoma who cannot be treated with cisplatin. This study will help to determine whether vinflunine in combination with gemcitabine will extend the ... | Inclusion Criteria:
* Clinical diagnosis of transitional cell carcinoma of the urothelium that is locally advanced or metastatic
* Ineligible for cisplatin-based therapy because of at least one of the following two medical conditions:
* Calculated creatinine clearance <=60 mL/min: OR
* New York Heart Association ... | 8,704 |
Study Objectives
Currently, there are no telemedical visits between patients and/or their relatives and a palliative physician for the evaluation of symptom and progress monitoring. This is done during visits of the patient by the coordinators and palliative physicians of the palliative network/PKD Münster (PKD = Palli... | Inclusion Criteria:
* Patients with indications to receive specialized palliative care for advanced malignant and non-malignant diseases
* Minimum age 18 years
* Signed informed consent
* Inpatient care in a normal ward or the palliative care unit at University Hospital Muenster
* Planned discharge to home environment... | 7,094 |
Study Objectives
The study objective is to evaluate the effectiveness of Traditional Chinese Medicine (TCM) five elements music therapy improving quality of life for patients with advanced cancer, as well as establishing the standard operating procedures (SOP) for it.
Conditions: Cancer
Intervention / Treatment:
OTHE... | Inclusion Criteria:
* Eligible participation will be enrolled based on diagnostic criteria.
* Advanced cancer patient with more than 50 scores of Karnofsky Performance Score (KPS).
* Diagnosis of advanced cancer
* Patients who are willing to be subject with taking part in this research voluntarily.
* No prior experien... | 8,849 |
Study Objectives
The purpose of this study was to see if giving Degarelix every month for 7 months then stop treatment for 7 months (intermittent therapy) would show a reduction of negative effects of androgen deprivation therapy by increasing the quality of life while keeping prostate specific antigen (PSA) levels sup... | Inclusion Criteria:
* >= 18 years.
* Raising PSA after prior treatment failure of localized prostate cancer.
* Has a histological confirmed non-metastatic cancer of the prostate (Gleason graded) based on the most current biopsy.
* Has a screening testosterone within normal range (>=1.5 ng/mL).
* Has Eastern Cooperativ... | 16,066 |
Study Objectives
Primary Objective:
* To assess the effect of 15-day repeated oral doses of 500 mg SAR302503 on the cytochrome P450 activity using a CYP probe cocktail (2C19, 2D6 and 3A4).
* To document pharmacokinetics of SAR302503 after repeated 500 mg oral daily doses.
Secondary Objectives:
* To assess the safety... | Inclusion criteria :
* Histologically or cytologically confirmed advanced solid malignancy that is metastatic or unresectable, and for which standard curative measures do not exist
* Signed informed consent
Exclusion criteria:
* Less than 18 years of age.
* Limited physical functioning (as evaluated by the Eastern C... | 9,808 |
Study Objectives
This phase I/II trial studies the side effects and best dose of cetuximab when given together with pembrolizumab in treating patients with colorectal cancer that has spread from the primary site (place where it started) to other places in the body (metastatic) or that cannot be removed by surgery. Mono... | Inclusion Criteria:
* Have a pathologically confirmed diagnosis of colorectal cancer, which is metastatic or otherwise unresectable
* Have received at least 1 prior systemic therapy in the metastatic or unresectable disease setting; patients who have recurred within six months of adjuvant chemotherapy are not required... | 2,455 |
Study Objectives
This is a non-randomized, open-label, single-institution phase I/II therapeutic trial of bavituximab and sorafenib in patients with advanced hepatocellular carcinoma (HCC). This study will be activated at the UT Southwestern Medical Center, comprised of The Harold C. Simmons Comprehensive Cancer Center... | Inclusion Criteria:
* Patients must have a diagnosis of hepatocellular carcinoma by at least one criterion listed below:
* Histologically confirmed.
* MRI or CT consistent with liver cirrhosis and at least one solid liver lesion >2 cm with early enhancement and delayed enhancement washout regardless of AFP.
... | 21,562 |
Study Objectives
Advanced colorectal cancer (ACRC) is a heterogeneous disease and classification of patients is nowadays inefficient. Roughly twenty per cent of patients present with favorable figures (less than 4 liver nodules and less than 5 cm) and are suitable for local treatments (surgery or local-ablative therapi... | Inclusion Criteria:
* Male or female, age >= 18 years
* Able to sign an informed consent form
* Advanced and/or metastatic colorectal cancer
* Colorectal cancer with KRAS wild type genotype
* At least one unidimensionally measurable lesion according to RECIST criteria (1.1 revised) (to be assessed <= 28 days prior to ... | 9,414 |
Study Objectives
The purpose of this study is to evaluate survival, response rate, safety and tolerability of YM155 given in combination with docetaxel as first-line treatment in subjects with human epidermal growth factor 2 non-overexpressing (HER2 negative) metastatic breast cancer.
Conditions: Breast Cancer
Interv... | Inclusion Criteria:
* Histologically- or cytologically-proven adenocarcinoma of the breast that is HER2 negative. Subjects with hormone receptor positive or negative status are eligible. Additionally, subjects with triple negative status (meaning estrogen receptor negative, progesterone receptor negative and HER2 nega... | 137 |
Study Objectives
This is a pilot study to assess the safety and measure image-based absorbed dose of 177Lu-P17-087/177Lu-P17-088 in patients with metastatic castration-resistant prostate cancer (mCRPC) who will undergo radioliagnd therapy using 177Lu-P17-087/177Lu-P17-088. All patients underwent whole-body 68Ga-PSMA PE... | Inclusion Criteria:
* All the patients had progressive metastatic castration-resistant prostate cancer that did not respond to androgen-suppression therapy and/or systemic chemotherapy;
* Distant metastases with high PSMA expression were confirmed on 68Ga-PSMA PET/CT within one week before the injection of 177Lu-P17-0... | 17,196 |
Study Objectives
The purpose of this study is to evaluate the safety, and tolerability of HLA-A\*2402 restricted epitope peptide VEGFR1 and VEGFR2 emulsified with Montanide ISA 51 in combination with gemcitabine
Conditions: Pancreatic Cancer
Intervention / Treatment:
BIOLOGICAL: VEGFR1-1084, VEGFR2-169, DRUG: Gemcita... | Inclusion Criteria:
DISEASE CHARACTERISTICS
* Locally advanced or metastatic pancreatic cancer precluding curative surgical resection and recurrent pancreatic cancer
* Measurable disease by CT scan
PATIENTS CHARACTERISTICS
* ECOG performance status 0-2
* Life expectancy > 3 months
* Laboratory values as follows:
... | 21,012 |
Study Objectives
Primary Objectives:
1. To determine the efficacy of administering multiple doses of intravenous (i.v.) busulfan at a dose of 130 mg/m2, to yield a systemic plasma drug exposure represented by a daily area under the plasma concentration versus time curve (AUC) of approximately 5,000 mMol-min for 4 days... | Inclusion Criteria:
* Patients with lymphoid malignancies, including Hodgkin's and non-Hodgkin's lymphoma (primary refractory or recurrent), or multiple myeloma (beyond first complete remission or unresponsive to therapy. Complete remission for multiple myeloma defined by absence of detectable paraprotein in serum and... | 7,539 |
Study Objectives
This is a prospective Belgian, multi-center, open-label, single-arm phase II study of weekly paclitaxel at a dose of 80mg/m² in combination with weekly carboplatin (AUC=2), for 12 weeks, followed by 4 cycles of dose dense epirubicin at a dose of 90 mg/m² and cyclophosphamide at a dose of 600 mg/m² ever... | Inclusion Criteria:
* Stage II-III operable triple negative (ER and PR < 10%; Her2 IHC 0-1 or FISH <2.0) breast cancer in women age > 18. For patients aged >= 65 years the G8 geriatric screening test should be > 14 (on a total of 17).
* Baseline mammography, US. MR of the breast on clinical indication.
* FNA of suspic... | 6,072 |
Study Objectives
This study was a single-arm, open-label, phase II study of PD-1 monoclonal antibody combined with anlotinib in the treatment of advanced non-small cell lung cancer (NSCLC) with EGFR uncommon mutations. Twenty-one patients of NSCLC harboring rare EGFR mutations after previous treatments, including a pla... | Inclusion Criteria:
* Sign written informed consent before any trial-related processes are implemented;
* Age >= 18 years old and <= 75 years old;
* Life expectancy exceeds 3 months;
* The investigator confirmed at least one measurable lesion according to the RECIST 1.1 standard. A measurable lesion located in the fie... | 20,642 |
Study Objectives
Protocol B8011001 is a Phase 1, open-label, multi-center, multiple-dose, dose escalation and expansion, safety, pharmacokinetics (PK), and pharmacodynamics (PD) study of PF-06801591 in previously treated adult patients with locally advanced or metastatic melanoma, SCCHN, ovarian carcinoma, sarcoma, NSC... | Inclusion Criteria (Part 2 Only):
* Histological or cytological diagnosis of locally advanced or metastatic NSCLC or urothelial carcinoma who have progressed on or were intolerant to standard of care systemic therapy, or for whom standard of care systemic therapy was refused (refusal must be documented) or unavailable... | 17,224 |
Study Objectives
This ia a single-arm, not-randomized, open-label phase II study. The purpose of this study is to evaluate the safety and efficacy of KN046 (PD-L1 /CTLA-4 Bispecific antibody) combined with Lenvatinib(TKI) for the treatment of advanced hepatocellular carcinoma.
Conditions: HCC
Intervention / Treatment... | Inclusion Criteria:
* Has a diagnosis of hepatocellular carcinoma confirmed by histology or cytology；
* Barcelona Clinic Liver Cancer (BCLC) Stage B or C；
* Age >=18 years or <=75 years for both genders；
* ECOG performance status: 0-1；
* Child Pugh score<=7；
* LVEF>=50% or above LLN of the research institution；
* Enou... | 17,403 |
Study Objectives
Three month treatment of acute VTE with Fragmin in pediatric cancer patients
Conditions: Venous Thromboembolism
Intervention / Treatment:
DRUG: dalteparin
Location: Norway, Spain, United States, Slovenia, Russian Federation
Study Design and Phases
Study Type: INTERVENTIONAL
Phase: PHASE2
Primary Pu... | Inclusion Criteria:
*
Exclusion Criteria:
* | 4,337 |
Study Objectives
Cannabis sativa is one of the most ancient psychotropic drugs known to humanity. Although most Western countries have outlawed the use of cannabis according to the UN Convention of Psychotropic Substances, an increasing number of states in the USA, Canada and several European countries allow the medici... | Inclusion Criteria:
* Age >18 years
* Histological or cytological documentation of malignancy
* Chemotherapy treatment
* Life expectancy of at least 6 months
* Able to sign informed consent.
Exclusion Criteria:
* Brain tumors or CNS metastasis
* Past cannabis use,
* Known cognitive diseases such as Alzheimer's disea... | 1,029 |
Study Objectives
Chemotharapy plus targeted therapy regimen, as an adjuvant therapy, can effectively reduce the rate of both intrahepatic and extrahepatic recurrence in initially unresectable CRLM patients. Those with KRAS/NRAS/BRAF mutated tumors or cycle of conversion therapy ≤ 4 can benefit more from chemotharapy pl... | Inclusion Criteria:
* Age >= 18 and <= 75 years;
* Histologically confirmed CRC;
* Initially unresectable synchronous liver metastases (LMs);
* Accepted conversion therapy and successfully converted into resectable status;
* Underwent R0 intestinal and hepatic resection;
* Accepted adjuvant therapy.
Exclusion Criteri... | 18,666 |
Study Objectives
Workplace exposure to secondhand cigarette smoke or environmental tobacco smoke (ETS)is widespread, effecting between 19 and 49% of the U.S. workforce. The first part of this study is designed to test whether exposure to ETS in the workplace effects a person's risk of developing chronic diseases such a... | Inclusion Criteria:
Non-smoker Work in a casino - on the casino floor or work as a bartender or cocktail server for at least 1 year Do not take antioxidant supplements Healthy - not diagnosed with any major chronic diseases.
Exclusion Criteria:
Blood pressure SBP>200,<85 DBP>100, <40 Pulse >120, <45 Cholesterol >400... | 14,957 |
Study Objectives
The purpose of this study is to test the safety and effectiveness of two investigational drugs (drugs that are not currently approved by the FDA) given in combination with radiation therapy or ablation.
Conditions: Metastatic Colorectal Cancer
Intervention / Treatment:
DRUG: durvalumab, DRUG: tremeli... | Inclusion Criteria:
* Be willing and able to provide written informed consent for the trial.
* Histologically- or cytologically- confirmed CRC.
* Metastatic CRC.
* Subjects have received at least two standard chemotherapy regimens for which they would be considered eligible (at least one containing a 5-fluoropyrimidin... | 19,368 |
Study Objectives
This protocol is a multicentric interventional phase II study from the French CML Intergroup (FILMC).
The core of the protocol is to explore the efficacy and safety of an optimization strategy consisting in the modulation of the dasatinib daily dose according to the results of repeated plasmatic level... | Inclusion Criteria:
* Male or female patient >= 18 years
* ECOG Performance Status score 0-2
* Philadelphia chromosome positive newly diagnosed (<= 3 months) CP-CML
* patients not previously treated except with hydroxyurea or imatinib (less than 4 weeks for imatinib)
* Signed written inform consent
* Adequate hepatic ... | 19,489 |
Study Objectives
This phase II trial is studying how well Akt inhibitor MK2206 works in treating patients with recurrent or metastatic head and neck cancer. Akt inhibitor MK2206 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Conditions: Recurrent Squamous Cell Carcinoma of t... | Inclusion Criteria:
* Histologically or cytologically confirmed non-keratinizing nasopharyngeal carcinoma that has recurred at locoregional and/or distant sites, and is not amenable to potentially curative radiotherapy or surgery
* Measurable disease according to the RECIST criteria
* Progressed =< 24 months of receiv... | 13,719 |
Study Objectives
This clinical study was planned in order to assess the superiority of INNOCELL Corp. "Immuncell-LC" in aspects of therapeutic efficacy and safety when administered with Temozolomide to glioblastoma patients when compared with the control group who did not receive administration of the drug.
Conditions... | Inclusion Criteria:
* Patients who, prior to the study, received explanation of the purpose and content of study and of characteristics of the test drug from the test administrator and have consented to the study by providing signature of self, guardian, or legal representative.
* Patients who are between 18 and 70 ye... | 4,774 |
Study Objectives
Acute myeloid leukemia (AML) is a heterogeneous group of diseases characterized by uncontrolled proliferation of the myeloid line of white blood cells and impaired production of normal blood cells. If untreated, patients die of infection or bleeding usually in a matter of weeks. CSL360 is a neutralisin... | Inclusion Criteria:
* Clinical diagnosis of acute myeloid leukemia
* Recent bone marrow biopsy
* Prior treatment or medically unfit for standard therapy
Exclusion Criteria:
* Peripheral blood blast count > 30 x 109/L, or rapidly progressive AML
* Previous solid organ transplant
* Active GvHD or immunosuppression
* C... | 6,712 |
Study Objectives
This trial was to evaluate the efficacy of intratumoral PTS injection in alleviating airway obstruction and dyspnea by improving the percentage of lumen patency of patients with central air way NSCLC tumor severe obstruction.
Conditions: Nsclc
Intervention / Treatment:
DRUG: Para-Toluenesulfonamide
... | Inclusion Criteria:
* Male or female inpatients, aged 18 to 83 years old.
* Patients with central air way non-small cell lung cancer (NSCLC) severe obstruction; definition of severe airway obstruction: >=1/2 trachea is obstructed by tumor; and/or block >=2/3 of primary bronchi, right and middle bronchi. And the longes... | 1,397 |
Study Objectives
The purpose of this trial is to assess the anti-tumour activity and safety of afatinib monotherapy in patients with urothelial tract carcinoma carrying ERBB2 or ERBB3 (Erythroblastic leukaemia viral oncogene homolog of the human epidermal growth factor family of receptors) mutations or ERBB2 amplificat... | Inclusion criteria:
* Recurrent or metastatic urothelial cancer
* Patients must have failed prior platinum based treatment (adjuvant or 1st line)
* Archival tissue sample available for biomarker testing at pre-screening and tissue banking.
* Patients should complete a pre-screening biomarker analysis and should fulfil... | 13,643 |
Study Objectives
TQB3616 capsule is a small molecule oral drug developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., which inhibits cyclin-dependent kinases 4 and 6 (CDK4/6). Its main mechanism of action is to inhibit the proliferation of tumor cells by reducing the phosphorylation level of retinoblastoma prot... | Inclusion Criteria:
* 1 Sign the informed consent form before the trial and fully understand the content, process and possible adverse reactions of the trial;
* 2 Be able to complete the study according to the requirements of the study protocol;
* 3 Subjects aged 18 to 65 years (including 18 and 65 years);
* 4 Body ma... | 3,910 |
Study Objectives
The purpose of this study is to find the highest dose level of study drug, CTT1403, that can be safely administered to patients with metastatic castration resistant prostate cancer (mCRPC).
Conditions: Prostate Cancer
Intervention / Treatment:
DRUG: CTT1403, DRUG: CTT1057, DRUG: 68Ga-PSMA-11
Locatio... | Inclusion Criteria:
* Patients must have histologically confirmed prostate adenocarcinoma that is metastatic and castration resistant (mCRPC).
* At least 3 metastatic foci avid for PSMA-specific PET agent (CTT1057) uptake on Screening PSMA PET.
* Has received docetaxol, ineligible for docetaxol, or refused docetaxol f... | 12,025 |
Study Objectives
The purpose of this study is to test the effect of the combination of sunitinib and bortezomib. We will see what effects it has on your cancer and find the highest dose of each agent that can be given without causing severe side effects.
Conditions: Solid Tumors
Intervention / Treatment:
DRUG: Suniti... | Inclusion Criteria:
Each patient must meet all of the following inclusion criteria to be enrolled in the study:
* Refractory advanced solid tumor that has failed standard therapy.
* ECOG PS <= 2
* Voluntary written informed consent before performance of any study-related procedure not part of normal medical care, wit... | 6,946 |
Study Objectives
The purpose of this study is to see if Cediranib in combination with FOLFOX is effective in treating metastatic colorectal cancer and to see how it compares with Avastin (Bevacizumab) in combination with FOLFOX.
Conditions: Colorectal Cancer
Intervention / Treatment:
DRUG: Cediranib, DRUG: Bevacizuma... | Inclusion Criteria:
* Clinical Diagnosis of colon or rectal cancer
* No prior systemic therapy for metastatic disease. Any adjuvant/neoadjuvant oxaliplatin therapy must have been received >12 months prior to study entry and adjuvant/neoadjuvant 5-FU must have been received >6 months prior to study entry.
Exclusion Cr... | 5,047 |
Study Objectives
This is a phase II study of the combination of oxaliplatin and trastuzumab as first or second line therapy in patients with stage IV, metastatic breast cancer
Conditions: Breast Cancer
Intervention / Treatment:
DRUG: Trastuzumab, DRUG: Oxaliplatin
Location: United States
Study Design and Phases
Stu... | Inclusion Criteria:
* Females >= 18 years of age
* Histologically confirmed breast cancer that is HER2/neu positive (3+ by IHC or FISH +) and evidence of metastatic disease. Tumor may be of any estrogen and progesterone receptor type
* Measurable disease by RECIST and an ECOG <= 2
* Patients with known evidence of bra... | 16,135 |
Study Objectives
Post-menopausal breast cancer patients will receive letrozole 2.5 mg daily for the treatment of breast cancer and will be randomized to a treatment group to receive either upfront zoledronic acid 4 mg IV 15-minute infusion every 6 months or delayed start zoledronic acid 4 mg IV 15-minute infusion every... | Inclusion Criteria:
* Stage I-IIIa breast cancer
* Postmenopausal
* Recent surgery for breast cancer
Exclusion Criteria:
* Metastatic disease
* Invasive bilateral disease
* Clinical or radiological evidence of existing fracture in spine or hip
Other protocol-defined inclusion / exclusion criteria may apply. | 8,739 |
Study Objectives
The objective of this study is to investigate the safety, pharmacokinetics, pharmacology and efficacy of ONO-4538 administered to Korean patients with advanced or recurrent solid tumors who are refractory or intolerant to standard therapy or for whom no appropriate treatment is available.
Conditions: ... | Inclusion Criteria:
* The treatment phase has been completed in the ONO-4538-13 study
Exclusion Criteria:
* The development of PD is identified by the principal or sub investigator according to the RECIST guideline (version 1.1) only in case in which the unplanned tumor assessment with diagnostic image is performed ... | 12,218 |
Study Objectives
A randomized controlled trial (RCT), 60 HNC patients who underwent radiotherapy (RT) with or without chemotherapy represented the sample of the study. They were assigned randomly into two equal groups, control group (CG) and study group (SG). Routine methods of nursing were given during radiotherapy in... | Inclusion Criteria:
* All patients were free from any skin diseases, All patients enrolled to this study signed their informed consent,All the patients who had Nasopharyngeal tumor receiving radiotherapy who participated in this study, diagnosed by an oncologist and confirmed by MRI, C.T and laboratory investigations)... | 5,653 |
Study Objectives
To determine the effect of increasing serum 25(OH)D from prevailing levels with vitamin D3 supplementation, while maintaining adequate calcium intake, on incidence of all-type cancer in a population sample of healthy postmenopausal women.
Conditions: Cancer
Intervention / Treatment:
DIETARY_SUPPLEMEN... | Inclusion Criteria:
* Age: >= 55 years
* Last menstrual period (LMP): >= 4 years
* Good general health
* Willingness to participate in this 4 year long study
* Able to give informed consent
* Able to live independently and travel to the Fremont Area Medical Center (FAMC) for study visits
Exclusion Criteria:
* Histor... | 22,343 |
Study Objectives
This study will investigate the drug-drug interactions (DDIs) between rucaparib and oral rosuvastatin (Arm A), and between rucaparib and oral ethinylestradiol and levonorgestrel (Arm B), with rucaparib as a perpetrator.
Conditions: Neoplasms
Intervention / Treatment:
DRUG: Rucaparib, DRUG: Rosuvastat... | Inclusion Criteria (All patients):
* Willing to sign the ICF and to comply with the study restrictions
* Body mass index (BMI) 18.0 to 35.0 kg/m2
* Histologically or cytologically confirmed advanced solid tumor
* Patients who, in the opinion of the Investigator, could potentially benefit from treatment with rucaparib
... | 14,263 |
Study Objectives
Adherence (or compliance with) a medication regimen is generally defined as the extent to which patients take medication as prescribed by their health care providers. The adherence to medications has close relation to effectiveness of the therapy. The primary objective of this study is to observe the a... | Inclusion Criteria:
* Diagnosis of breast cancer, prostate cancer, multiple myeloma and other skeletal events causing tumors
* Bone metastases
* Therapy with clodronate (1600 mg per day, 800 mg tablets) according to SmPC (Summary of Product Characteristics) Bonefos.
* By agreeing to usage of patients diaries and goodw... | 7,175 |
Study Objectives
The goal of this clinical research study is to learn how dasatinib affects biomarker levels in patients with malignant pleural mesothelioma that may be able to be removed by surgery. The safety and effectiveness of this drug will also be studied.
This research study is financially supported by the Uni... | Inclusion Criteria:
* Patients with potentially resectable malignant pleural mesothelioma, IMIG stage I-III
* Subject, age >= 18 years
* Any patient who is able to tolerate general anesthesia for the extended surgical staging and the definitive surgical resection.
* No prior chemotherapy for mesothelioma within the la... | 2,495 |
Study Objectives
The purpose of this study is to determine the maximum tolerated dose of Genexol®-PM plus Carboplatin and evaluate the efficacy and safety of Genexol®-PM plus Carboplatin regimen in subjects with advanced ovarian cancer.
Conditions: Ovarian Cancer
Intervention / Treatment:
DRUG: Genexol-PM 220mg/㎡, Ca... | Inclusion Criteria:
* Women >= 18 years old.
* Signed informed consent before inclusion.
* Subjects who have histologically or cytologically confirmed advanced epithelial ovarian cancer.(FIGO IIIB-IV)
* Subjects who have measurable disease by RECIST after debulking surgery.
* ECOG performance status of 0, 1, or 2.
* E... | 12,405 |
Study Objectives
The purpose of this study is to determine if participants with metastatic colorectal cancer live longer without their cancer progressing when treated with standard chemotherapy, standard chemotherapy plus ramucirumab, or standard chemotherapy plus icrucumab.
Conditions: Colon Cancer, Rectal Cancer
In... | Inclusion Criteria:
* Disease progression on an irinotecan-based first-line chemotherapy regimen (ie FOLFIRI or CAPIRI [capecitabine + irinotecan], with or without bevacizumab)
* Age >= 18 years
* Life expectancy of >= 6 months
* Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-1 at study entry
* Agre... | 746 |
Study Objectives
This is an open label, multi-center, Phase 1/2 study of BBI608 administered in combination with immunotherapy in adult patients with advanced cancers. The goal of the study is to determine the RP2D of BBI608 in combination with each of the immunotherapeutic agents.
Conditions: Cancer
Intervention / T... | Inclusion criteria:
* Signed written informed consent must be obtained and documented according to International Conference on Harmonisation (ICH) and local regulatory requirements
* A histologically or cytologically confirmed cancer that is metastatic, unresectable, or recurrent and for which treatment with ipilimuma... | 20,913 |
Study Objectives
This phase II trial studies how well pembrolizumab and lenvatinib work in treating patients with differentiated thyroid cancer that has spread to other places in the body or has come back and cannot be removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the bod... | Inclusion Criteria:
* Locally recurrent and unresectable and/or distant metastatic differentiated thyroid cancer (DTC), histologically or cytologically confirmed; the diagnosis of DTC includes the following subtypes: papillary thyroid cancer (PTC) (including but not limited to variants such as follicular variant, tall... | 12,689 |
Study Objectives
Fentanyl is expected to suppress tracheal tube-induced cough during emergence from general anaesthesia through binding to its receptors in the brainstem. However, it has not been proven if fentanyl has a complication-free, dose-dependent effect on cough suppression during emergence from sevoflurane ana... | Inclusion Criteria:
* the patients undergoing general anaesthesia for elective thyroidectomy due to thyroid neoplasm.
* ASA I-II.
* 20-59 years old.
* female only.
Exclusion Criteria:
* signs of difficult intubation.
* risks for perioperative pulmonary aspiration.
* history of chronic respiratory disease.
* recent u... | 2,701 |
Study Objectives
This study is a pilot study to evaluate high-dose conformal radiation therapy (HDCRT) administered in combination with pembrolizumab in patients with solid tumors.
Conditions: Solid Tumor
Intervention / Treatment:
RADIATION: High-Dose Conformal Radiation Therapy, DRUG: Pembrolizumab
Location: United... | Inclusion Criteria:
* Subjects must have a histologically or cytologically proven advanced solid tumor malignancy for which palliative radiation is recommended. In solid tumors where pembrolizumab has been approved for use, patients may receive pembrolizumab as indicated, in the context of this protocol. In solid tumo... | 14,239 |
Study Objectives
The purposes of this study are: To determine the maximum tolerated dose of Gemcitabine and Platinol followed by Pemetrexed and Gemcitabine in patients with advanced or metastatic transitional cell carcinoma of the urothelium; To determine the safety of Gemcitabine and Platinol followed by Pemetrexed an... | Inclusion Criteria:
* Biopsy-proven metastatic bladder cancer
* No prior chemotherapy for metastatic disease except before or after surgery, which was completed 6 months before enrollment
* Prior radiation allowed, if it is not the only site of measurable disease and if completed 3 weeks before enrollment
* 18 years o... | 18,467 |
Study Objectives
This Phase I study is designed to evaluate the systemic exposure and safety of KX2-391 Ointment in adult subjects when applied to an area of skin containing at least 5 clinically typical, visible, and discrete Actinic Keratosis lesions on the face or balding scalp.
Conditions: Actinic Keratoses
Inter... | Inclusion Criteria:
* Males and females >=18 years old.
* Able to comprehend and are willing to sign an informed consent form (ICF).
* At least 5 clinically typical, visible, and discrete AKs on 25 cm2 of the face or balding scalp.
* Subjects who, in the judgment of the Investigator, are in good general health based o... | 3,669 |
Study Objectives
Standard treatment for locally advanced cancer of the rectum is preoperative chemoradiotherapy with 5-Fluorouracil (5-FU) plus 4 cycles of postoperative chemotherapy with 5-FU. According to our previous study (CAO/ARO/AIO-94, published in the New England Journal of Medicine 2004; 351:1731-40) this trea... | Inclusion Criteria:
* Minimum age: 18 years
* Histologically proven, advanced primary carcinoma of the rectum (tumor ? 12cm from the anal verge, with clinically staged T3/4 or any node-positive disease
* No prior therapy except a diverting stoma
* ECOG PS less than or equal 2
* Adequate bone marrow function: Leukocyte... | 4,783 |
Study Objectives
The purpose of this study is to determine the clinical benefits of using a rapidly cycling, non-cross reactive regimen of FDA-approved prostate cancer therapeutic agents in the management of castration resistant prostate cancer. The hypothesis is that the identification of optimal combinations and sequ... | Inclusion Criteria:
* Histologically or cytologically confirmed adenocarcinoma of the prostate
* Metastatic castrate resistant prostate cancer, defined by progressive disease based on either rising PSA, new bone metastases, or progression of measurable disease on standard imaging, according to PCWG2 guidelines, despit... | 4,851 |
Study Objectives
This multicenter, open-label, dose-escalating study will assess the safety, tolerability, and pharmacokinetics of DMOT4039A in participants with unresectable pancreatic or platinum-resistant ovarian cancer. Cohorts of participants will receive multiple ascending intravenous doses of DMOT4039A.
Conditi... | Inclusion Criteria:
* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
* Histologically documented, incurable, locally advanced or metastatic disease for which no standard therapy exists, consisting of one of the following: Unresectable pancreatic ductal adenocarcinoma or platinum-resistant ovarian ... | 12,029 |
Study Objectives
This study investigates the safety/toxicity and potential anti-tumor activity of sequential administration of nivolumab and escalating doses of the mTOR inhibitor ABI-009 in advanced Ewing's sarcoma, PEComa, epithelioid sarcoma, desmoid tumor, chordoma, non-small cell lung cancer, small cell lung cance... | Inclusion Criteria:
A patient will be eligible for inclusion in this study only if all of the following criteria are met:
* Patients must have a histologically confirmed diagnosis of Ewing's sarcoma, PEComa, epithelioid sarcoma, desmoid tumor, chordoma, non-small cell lung cancer, small cell lung cancer, urethelial c... | 7,317 |
Study Objectives
Prospective, non-interventional, multi-center study. Patients affected by Hepatocellular Carcinoma (HCC) who are candidates for systemic therapy and in whom a decision to treat with sorafenib has been made. Aim of this non-interventional, post-marketing study is to evaluate the efficacy of sorafenib in... | Inclusion Criteria:
* Patients with histologically/cytologically confirmed HCC or radiographically diagnosed as per AASLD criteria, who are candidates for systemic therapy and for whom a decision to treat with sorafenib has been made
* Patients must have signed the informed consent form
* Patients must have a life exp... | 8,103 |
Study Objectives
This clinical study is in subjects who are 18 years old or older with locally advanced pancreatic cancer who have not received prior treatment for their pancreatic cancer. The study treats all subjects with nab-Paclitaxel plus gemcitabine for approximately 6 months of treatment. Subjects who complete t... | Inclusion Criteria:
* Non- metastasis, unresectable, adenocarcinoma pancreatic cancer patients
* No prior anticancer therapy for pancreatic cancer
*>= 18 years of age with a performance status of 0 or 1
*Adequate complete blood counts, hepatic function, and renal function
* Signed informed Consent
Exclusion Crite... | 9,948 |
End of preview. Expand in Data Studio
README.md exists but content is empty.
- Downloads last month
- 4